Altai Capital Urges Sale of OraSure Technologies to Boost Share Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy OSUR?
Source: seekingalpha
- Share Price Potential: Altai Capital is advocating for a potential sale of OraSure Technologies, suggesting a share price valuation between $4.54 and $6.60, representing a premium of 42% to 107% over the current price, indicating significant value in a sale scenario.
- Board Nominations: Altai Capital is reiterating its call for the inclusion of its President Rishi Bajaj and Digital Diagnostics CEO John Bertrand on OraSure's board, aiming to steer the company towards a strategic direction that could enhance its market valuation.
- Acquisition Interest: Healthcare entrepreneur Ron Zwanziger has reconfirmed his interest in acquiring OraSure, having previously proposed an all-cash deal valued at $3.50 to $4.00 per share, highlighting ongoing market interest in the company.
- Market Reaction: Despite the acquisition proposals generating attention, OraSure's shares fell by 2.9%, reflecting market uncertainty regarding the company's future prospects, which may impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OSUR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OSUR
About OSUR
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altai Capital Urges Sale of OraSure Technologies to Boost Share Price
- Share Price Potential: Altai Capital is advocating for a potential sale of OraSure Technologies, suggesting a share price valuation between $4.54 and $6.60, representing a premium of 42% to 107% over the current price, indicating significant value in a sale scenario.
- Board Nominations: Altai Capital is reiterating its call for the inclusion of its President Rishi Bajaj and Digital Diagnostics CEO John Bertrand on OraSure's board, aiming to steer the company towards a strategic direction that could enhance its market valuation.
- Acquisition Interest: Healthcare entrepreneur Ron Zwanziger has reconfirmed his interest in acquiring OraSure, having previously proposed an all-cash deal valued at $3.50 to $4.00 per share, highlighting ongoing market interest in the company.
- Market Reaction: Despite the acquisition proposals generating attention, OraSure's shares fell by 2.9%, reflecting market uncertainty regarding the company's future prospects, which may impact investor confidence.
See More
Altai Capital Calls for Board Change at OraSure Technologies
- Shareholder Value Erosion: Altai Capital Management, holding approximately 5% of OraSure's shares, highlights the company's significant underperformance over five and ten years, with management's strategic failures resulting in a 60% loss for shareholders, necessitating board changes to protect investor value.
- Lack of Accountability: Independent directors at OraSure own less than 1% of shares yet receive over $250,000 annually, lacking financial risk for decisions that have harmed shareholder value, prompting Altai to argue for greater shareholder representation on the board.
- Misalignment of Executive Compensation: Over 90% of CEO Carrie Eglinton Manner's compensation is not linked to stock performance, with her total earnings reaching $15 million since 2023 while shareholders have suffered substantial losses, indicating a severe disconnect between executive incentives and shareholder interests.
- Need for Strategic Review: Altai calls for a comprehensive strategic review of OraSure, including the potential sale of the entire business, to ensure optimal returns for shareholders, pledging to advocate for all shareholder interests upon board appointment.
See More
OraSure Technologies Q4 2025 Earnings Call Insights
- Financial Performance Overview: OraSure reported total revenue of $26.8 million in Q4 2025, with core revenue at $26.7 million, driven by $15.1 million from Diagnostic Products and $9.1 million from Sample Management Solutions, while gross margin improved to 41%, reflecting the company's efforts to stabilize revenue.
- Product Launch Plans: The company plans to launch two new products in mid-2026, including a rapid molecular self-test and an at-home urine collection device, marking significant milestones in its innovation roadmap and expected to drive future revenue growth.
- International Market Expansion: OraSure expanded its presence in Canada with the launch of the OraQuick HIV Self-Test and signed framework agreements with 14 African countries, highlighting the company's focus on global markets and their growth potential.
- Future Outlook: The CFO projected that new product launches in the second half of 2026 will drive revenue growth, and despite regulatory uncertainties, the company remains committed to achieving profitable growth through cost control and operational efficiency improvements.
See More
OraSure Technologies Schedules Q4 2025 Earnings Call for February 25, 2026
- Earnings Call Announcement: OraSure Technologies has scheduled its earnings conference call for Q4 2025 on February 25, 2026, at 5 PM ET, to report financial results and business developments to investors.
- Webcast Availability: The conference call will be available via webcast on OraSure's investor relations page, requiring investors to register and access the link at least 10 minutes prior to the call to ensure participation.
- Company Overview: OraSure Technologies focuses on transforming health through actionable insights and decentralizing diagnostics, enhancing healthcare access, quality, and value with innovative rapid tests and sample management solutions.
- Global Sales Network: OraSure's product portfolio, which includes rapid diagnostic tests and sample collection devices, is sold globally to clinical laboratories, hospitals, physician offices, and public health organizations, underscoring its leadership position in the global healthcare market.
See More
OraSure Technologies Nominates Board Candidates Amid Ongoing Refreshment Efforts
- Board Nominations: Altai Capital has nominated two candidates, including founder Rishi Bajaj, for election to OraSure's Board, indicating investor interest in corporate governance that may influence shareholder perceptions of the company's future direction.
- Board Refreshment: Since 2022, OraSure's Board has seen the departure of seven directors and the addition of three independent directors, including healthcare investor Steven K. Boyd in October 2025, aimed at enhancing industry perspectives and oversight capabilities.
- Shareholder Meeting Plans: OraSure will review Altai's nominations at its 2026 Annual Meeting and provide recommendations in a proxy statement to be filed with the SEC, ensuring shareholders have comprehensive information and choices during the election process.
- Advisory Support: With Evercore as financial advisor, Goodwin Procter LLP as legal counsel, and Joele Frank as strategic communications advisor, OraSure is bolstering its governance and shareholder communication efforts, enhancing transparency and trust among investors.
See More
Altai Capital Nominates Two Directors to OraSure's Board, Stock Rises 1.7%
- Board Nominations: Altai Capital has nominated Digital Diagnostics CEO John Bertrand and Altai President Rishi Bajaj to OraSure's board, indicating a proactive approach to governance aimed at improving the company's stock performance.
- Shareholder Concerns: Holding a 5.2% stake in OraSure, Altai Capital previously sent a letter to the board expressing concerns about the company's 'significant share price underperformance,' urging the board to consider alternative strategies to enhance shareholder value.
- Stock Price Reaction: Following the nomination announcement, OraSure's stock rose by 1.7%, reflecting market optimism regarding the potential positive changes that the new board candidates may bring, thereby boosting investor confidence in the company's future.
- Growth Outlook: OraSure is signaling a return to growth in 2026 while expanding its diagnostics portfolio through the acquisition of BioMedomics, indicating that the company is taking steps to address market challenges and enhance its competitive position.
See More
Altai Capital Urges Sale of OraSure Technologies to Boost Share Price
- Share Price Potential: Altai Capital is advocating for a potential sale of OraSure Technologies, suggesting a share price valuation between $4.54 and $6.60, representing a premium of 42% to 107% over the current price, indicating significant value in a sale scenario.
- Board Nominations: Altai Capital is reiterating its call for the inclusion of its President Rishi Bajaj and Digital Diagnostics CEO John Bertrand on OraSure's board, aiming to steer the company towards a strategic direction that could enhance its market valuation.
- Acquisition Interest: Healthcare entrepreneur Ron Zwanziger has reconfirmed his interest in acquiring OraSure, having previously proposed an all-cash deal valued at $3.50 to $4.00 per share, highlighting ongoing market interest in the company.
- Market Reaction: Despite the acquisition proposals generating attention, OraSure's shares fell by 2.9%, reflecting market uncertainty regarding the company's future prospects, which may impact investor confidence.
See More
Altai Capital Calls for Board Change at OraSure Technologies
- Shareholder Value Erosion: Altai Capital Management, holding approximately 5% of OraSure's shares, highlights the company's significant underperformance over five and ten years, with management's strategic failures resulting in a 60% loss for shareholders, necessitating board changes to protect investor value.
- Lack of Accountability: Independent directors at OraSure own less than 1% of shares yet receive over $250,000 annually, lacking financial risk for decisions that have harmed shareholder value, prompting Altai to argue for greater shareholder representation on the board.
- Misalignment of Executive Compensation: Over 90% of CEO Carrie Eglinton Manner's compensation is not linked to stock performance, with her total earnings reaching $15 million since 2023 while shareholders have suffered substantial losses, indicating a severe disconnect between executive incentives and shareholder interests.
- Need for Strategic Review: Altai calls for a comprehensive strategic review of OraSure, including the potential sale of the entire business, to ensure optimal returns for shareholders, pledging to advocate for all shareholder interests upon board appointment.
See More
OraSure Technologies Q4 2025 Earnings Call Insights
- Financial Performance Overview: OraSure reported total revenue of $26.8 million in Q4 2025, with core revenue at $26.7 million, driven by $15.1 million from Diagnostic Products and $9.1 million from Sample Management Solutions, while gross margin improved to 41%, reflecting the company's efforts to stabilize revenue.
- Product Launch Plans: The company plans to launch two new products in mid-2026, including a rapid molecular self-test and an at-home urine collection device, marking significant milestones in its innovation roadmap and expected to drive future revenue growth.
- International Market Expansion: OraSure expanded its presence in Canada with the launch of the OraQuick HIV Self-Test and signed framework agreements with 14 African countries, highlighting the company's focus on global markets and their growth potential.
- Future Outlook: The CFO projected that new product launches in the second half of 2026 will drive revenue growth, and despite regulatory uncertainties, the company remains committed to achieving profitable growth through cost control and operational efficiency improvements.
See More
OraSure Technologies Schedules Q4 2025 Earnings Call for February 25, 2026
- Earnings Call Announcement: OraSure Technologies has scheduled its earnings conference call for Q4 2025 on February 25, 2026, at 5 PM ET, to report financial results and business developments to investors.
- Webcast Availability: The conference call will be available via webcast on OraSure's investor relations page, requiring investors to register and access the link at least 10 minutes prior to the call to ensure participation.
- Company Overview: OraSure Technologies focuses on transforming health through actionable insights and decentralizing diagnostics, enhancing healthcare access, quality, and value with innovative rapid tests and sample management solutions.
- Global Sales Network: OraSure's product portfolio, which includes rapid diagnostic tests and sample collection devices, is sold globally to clinical laboratories, hospitals, physician offices, and public health organizations, underscoring its leadership position in the global healthcare market.
See More
OraSure Technologies Nominates Board Candidates Amid Ongoing Refreshment Efforts
- Board Nominations: Altai Capital has nominated two candidates, including founder Rishi Bajaj, for election to OraSure's Board, indicating investor interest in corporate governance that may influence shareholder perceptions of the company's future direction.
- Board Refreshment: Since 2022, OraSure's Board has seen the departure of seven directors and the addition of three independent directors, including healthcare investor Steven K. Boyd in October 2025, aimed at enhancing industry perspectives and oversight capabilities.
- Shareholder Meeting Plans: OraSure will review Altai's nominations at its 2026 Annual Meeting and provide recommendations in a proxy statement to be filed with the SEC, ensuring shareholders have comprehensive information and choices during the election process.
- Advisory Support: With Evercore as financial advisor, Goodwin Procter LLP as legal counsel, and Joele Frank as strategic communications advisor, OraSure is bolstering its governance and shareholder communication efforts, enhancing transparency and trust among investors.
See More
Altai Capital Nominates Two Directors to OraSure's Board, Stock Rises 1.7%
- Board Nominations: Altai Capital has nominated Digital Diagnostics CEO John Bertrand and Altai President Rishi Bajaj to OraSure's board, indicating a proactive approach to governance aimed at improving the company's stock performance.
- Shareholder Concerns: Holding a 5.2% stake in OraSure, Altai Capital previously sent a letter to the board expressing concerns about the company's 'significant share price underperformance,' urging the board to consider alternative strategies to enhance shareholder value.
- Stock Price Reaction: Following the nomination announcement, OraSure's stock rose by 1.7%, reflecting market optimism regarding the potential positive changes that the new board candidates may bring, thereby boosting investor confidence in the company's future.
- Growth Outlook: OraSure is signaling a return to growth in 2026 while expanding its diagnostics portfolio through the acquisition of BioMedomics, indicating that the company is taking steps to address market challenges and enhance its competitive position.
See More
